A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
University of Minnesota Libraries Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|